Genentech's New and Improved Herceptin

Jun 4, 2012, 00:00 AM by Michael Croft

Xconomy | Genentech and ImmunoGen have released early results of an experimental drug, trastuzumab emtansine (T-DM1), that targets HER2-expressing breast cancers. The drug combines the targeting capabilities of Genetech's Herceptin with an additional tumor toxin thanks to a chemical linker from ImmunoGen.

June 4, 2012 | Genentech and ImmunoGen have released early results of an experimental drug, trastuzumab emtansine (T-DM1), that targets HER2-expressing breast cancers. The drug combines the targeting capabilities of Genetech's Herceptin with an additional tumor toxin thanks to a chemical linker from ImmunoGen. The presented research suggests that the new therapy shrinks tumors in more patients, causes fewer side effects, and keeps patients in remission longer. Xconomy